Andrew Zloza, MD, PhD
VP, Translational Research
Dr. Zloza is a renowned outcomes-driven leader in the fields of immunology and cancer (immuno-oncology) translational and clinical research with more than 15 years of experience in the academic and biotechnology sectors. He has a history of leading teams from concept to clinical trial, and most recently led a discovery program as Senior Director of Translational Science at Primevax Immuno-Oncology, Inc. Dr. Zloza’s successes at identifying novel therapies and unraveling mechanisms have led to IND-enabling studies, high-tier publications, and NIH R01, R44 (SBIR), and foundation funding awards. Dr. Zloza previously served as a tenured Associate Professor in the Department of Internal Medicine, Division of Hematology, Oncology, and Cell Therapy and Division of Translational and Precision Medicine. Prior to that he was the Section Chief of Surgical Oncology Research and founding Director of the Immune Monitoring Shared Resource at Rutgers Cancer Institute of New Jersey. Dr. Zloza earned his BS in Chemical Engineering at the Illinois Institute of Technology (IIT) as part of the IIT/Rush University Honors Program in Engineering and Medicine. He completed MD and PhD (Immunology/Microbiology) studies as part of the Rush Physician Scientist MD PhD Program. He further trained as a Ruth L. Kirschstein National Research Service Award (NRSA) postdoctoral fellow in Cancer Immunology and Tumor Vaccine Research at The University of Chicago. In recognition of his successes, Dr. Zloza has held positions on national committees, including the NCI Cancer Therapy Evaluation Program (CTEP) and has received numerous awards, including the Chambers- eBioscience Memorial Award by the American Association of Immunologists.